Reduced levels of lysyl oxidase in plasma extracellular vesicles: a potential biomarker associated with the risk of brain metastases in lung adenocarcinoma - Scorecard - MDSpire
Advertisement
Reduced levels of lysyl oxidase in plasma extracellular vesicles: a potential biomarker associated with the risk of brain metastases in lung adenocarcinoma
Clinical Scorecard: Reduced levels of lysyl oxidase in plasma extracellular vesicles: a potential biomarker associated with the risk of brain metastases in lung adenocarcinoma
At a Glance
Category
Detail
Condition
Lung adenocarcinoma with brain metastases
Key Mechanisms
Tumor-derived extracellular vesicles (TDEVs) facilitate organ-specific metastasis through molecular interactions.
Target Population
Patients diagnosed with stage IV lung adenocarcinoma, particularly those at risk for brain metastases.
Care Setting
Oncology clinics and research institutions.
Key Highlights
30-50% of lung adenocarcinoma patients develop brain metastases.
Current treatments yield a median overall survival of under 12 months.
Plasma exosomal proteins may serve as non-invasive biomarkers for predicting brain metastases.
Guideline-Based Recommendations
Diagnosis
Utilize MRI for early detection of brain metastases.
Management
Consider liquid biopsy for monitoring high-risk populations.
Monitoring & Follow-up
Employ proteomic profiling and immunohistochemistry for biomarker validation.
Risks
Neurosurgical biopsy carries risks; liquid biopsy offers a safer alternative.
Patient & Prescribing Data
260 patients with pathologically confirmed stage IV lung adenocarcinoma.
Liquid biopsy may improve early identification and intervention for brain metastases.
Clinical Best Practices
Incorporate liquid biopsy techniques in routine monitoring of lung adenocarcinoma patients.
Utilize proteomic analysis to identify potential biomarkers for brain metastasis.
